Thursday, September 30, 2004

Merck should invest in Rolaids

Merck's product pipeline has been rather weak, which in drug company terms means several years of hard times when the patents start expiring. Now Merck is pulling Vioxx from the shelves effective immediately because of increased risk of heart attack and stroke after 18 months on the drug.